Nutriband Inc. reported its financial results for the six months ended July 31, 2025, highlighting a record revenue of $1.29 million, up 50.87% year-over-year. The company maintains a cash position of $6.9 million, supporting its development efforts for AVERSA Fentanyl. Nutriband is progressing with its kinesiology tape contract manufacturing services through its Pocono Pharma subsidiary. The company is advancing the development of its lead product, AVERSA Fentanyl, which has been granted a Type C meeting on September 18th. The NDA submission will rely primarily on data from a single phase 1 Human Abuse Potential study, as no Phase 2 or Phase 3 clinical trials are required. If approved, AVERSA Fentanyl could become the first abuse-deterrent transdermal patch available globally, with potential peak annual sales estimated between $80 million and $200 million. Additionally, AVERSA Buprenorphine, Nutriband's second application for AVERSA, is projected to reach peak annual sales of up to $130 million. As of July 31, 2025, Nutriband's total assets are valued at $10.17 million, with stockholders' equity amounting to $8.5 million.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nutriband Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9526428-en) on September 10, 2025, and is solely responsible for the information contained therein.
Comments